(3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-5-methyl hexanoic acid | 77119-88-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-5-methyl hexanoic acid
• 英文别名: 3-{[(Tert-butoxy)carbonyl]amino}-2-hydroxy-5-methylhexanoic acid；2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid
• CAS: 77119-88-1
• 化学式: C₁₂H₂₃NO₅
• mdl: MFCD24391025
• 分子量: 261.318
• InChiKey: DJZCWTDKDFJARG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-5-methyl hexanoic acid 在 三氟乙酸 作用下， 生成 (2R,3S)-3-amino-2-hydroxy-5-methylhexanoic acid
  参考文献：
  名称：

  Synthesis of (2S,3R)-3-amino-2-hydroxy-5-methylhexanoic acid derivatives. Application to the synthesis of amastatin, an inhibitor of aminopeptidases

  摘要：

  DOI：

  10.1021/jo01300a004
• 作为产物：
  描述：

  N-叔丁氧羰基-L-亮氨醇 生成 (3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-5-methyl hexanoic acid
  参考文献：
  名称：

  LISSENCEPHALY THERAPEUTIC AGENT

  摘要：

  公开号：

  EP2647386B1

文献信息

• [EN] ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF<br/>[FR] DERIVE D'ALPHA-CETOAMIDE, SON PROCEDE DE PRODUCTION ET D'UTILISATION
  申请人：SENJU PHARMA CO

  公开号：WO2005056519A1

  公开（公告）日：2005-06-23

  The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optionally substituted by a phenyl; and R3 is a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a fused polycyclic hydrocarbon group), which is well absorbed orally, exhibits durability of good blood level and has potent calpain inhibitory activity.

  本发明提供了一种化合物，其化学式表示为（I）：（插入化学式）（其中R1是由低烷基取代的低烷氧基或杂环基，或者是杂环基；R2是可选择地由苯基取代的低烷基；R3是可选择地由卤素、低烷氧基或苯基取代的低烷基，或者是融合的多环碳氢基），该化合物在口服后被很好地吸收，表现出良好的血液水平持久性，并具有强大的钙蛋白酶抑制活性。
• Synthesis and CD Spectra of Fluoro- and Hydroxy-Substituted -Peptides
  作者：François Gessier、Christian Noti、Magnus Rueping、Dieter Seebach

  DOI：10.1002/hlca.200390150

  日期：2003.6

  as well as the patterns of the CD spectra (Figs. 3–5) depend upon constitution (OH, F, F2 substitution) and configuration (l or u) of the amino acid residues, upon the total number of OH and F substituents in the peptide chain, and upon the solvent used (H2O, MeOH, CF3CH2OH, (CF3)2CHOH). No reliable clues regarding the structures can be obtained from these CD spectra. Only a full NMR analysis will

  β -氨基酸1 - 3与在OH和F的取代基α位上已经制备（方案）从天然（小号） - α -氨基酸的丙氨酸，缬氨酸和亮氨酸，以及掺入到β -hexa-和β -heptapeptides 4 - 12。肽合成是根据常规的溶液策略（Boc / Bn保护）与片段偶联进行的。具有（系列a）和不具有（系列b）的新β肽末端保护以HPLC纯形式分离，并通过NMR光谱和MALDI质谱进行表征。CD光谱的化学性质和谱图（图3-5）取决于OH总数，氨基酸残基的组成（OH，F，F 2取代）和构型（l或u）肽链中的F和F取代基，以及所用溶剂（H 2 O，MeOH，CF 3 CH 2 OH，（CF 3）2 CHOH）上。从这些CD光谱不能获得关于结构的可靠线索。只有一个完整的NMR分析就能回答的问题：一）哪些已知的β肽二级结构（图1和2）与OH和F衍生物相容？b）极性和/或氢键主链取代基是否增强了新的二级结构？此外，
• New renin-inhibitory peptides and their use
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0152255A2

  公开（公告）日：1985-08-21

  Compounds of formula wherein R' represents alkyl having an α-amino or protected α-amino substituent and an aryl, heterocyclic or heterocyclic- dithio substituent; R2 represents a variety of aliphatic and cycloaliphatic hydrocarbon groups, which may be substituted; R3 represents isobutyl, sec-butyl, benzyl or (C3-CS cyclo- elkyl)methyl; and X represents a group of formula -CH(-A-R")-Y) (in which: A represents a single bond or an alkylene group: R4 represents an optionally protected carboxy group, an optionally N-substituted carbamoyl group, an optionally N-substituted carbazoyl group or an acyl group; and Y represents a hydroxy group, a mercapto group or a formyl group), or a group of formula -P(O)(R5)-OH (in which R5 represents an alkyl group having at least one optionally protected carboxy, N-substituted carbamoyl, optionally N-substituted carbazoyl, C2-C7 aliphatic carboxylic acyl or aromatic carboxylic acyl substituent)]; and their salts are renin inhibitors, which may be used in the treatment of angiotensin-induced hypertension.

  式中的化合物 式中 R'代表具有α-氨基或受保护α-氨基取代基的烷基，以及芳基、杂环或杂环-二硫代基； R2 代表各种可被取代的脂肪族和环脂族烃基； R3 代表异丁基、仲丁基、苄基或（C3-CS 环烷基）甲基；以及 X 代表式 -CH(-A-R")-Y)的基团 其中A 代表单键或亚烷基：R4 代表任选受保护的羧基、任选 N-取代的氨基甲酰基、任选 N-取代的咔唑酰基或酰基；Y 代表羟基、巯基或甲酰基），或 式中-P(O)(R5)-OH 的基团 (其中 R5 代表具有至少一个任选保护的羧基、N-取代的氨基甲酰基、任选 N-取代的咔唑酰基、C2-C7 脂肪族羧酰基或芳香族羧酰基取代基的烷基）]；它们的盐类是肾素抑制剂，可用于治疗血管紧张素诱导的高血压。
• Novel inhibitors of hepatitis C NS3–NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid
  作者：Srikanth Venkatraman、F. George Njoroge、Wanli Wu、Viyyoor Girijavallabhan、Andrew J. Prongay、Nancy Butkiewicz、John Pichardo

  DOI：10.1016/j.bmcl.2005.12.046

  日期：2006.3

  Prolonged hepatitis C infection is the leading cause for cirrhosis of the liver and hepatocellular carcinoma. The etiological agent HCV virus codes a single polyprotein of similar to 3000 amino acids that is processed with the help of a serine protease NS3A to produce structural and non-structural proteins required for viral replication. Inhibition of NS3 protease can potentially be used to develop drugs for treatment of HCV infections. Herein, we report the development of a series of novel NS3 serine protease inhibitors derived from 2-aza-bicyclo[2.2.1]-heptane carboxylic acid with potential therapeutic use for treatment of HCV infections. (C) 2005 Elsevier Ltd. All rights reserved.
• Stereoselective synthesis of (−)-N-Boc-statine and (−)-N-Boc-Norstatine
  作者：G. Veeresha、Apurba Datta

  DOI：10.1016/s0040-4039(97)01108-8

  日期：1997.7

  An efficient synthesis of optically pure N-Boc-statine (9) and N-Boc-norstatine (11) has been developed via a syn selective Grignard reaction of N-Boc-leucinal with allyl- or vinylmagnesium bromide. (C) 1997 Published by Elsevier Science Ltd.